The latest announcement is out from Nkarta (NKTX).
Nkarta, Inc. has appointed Nadir Mahmood, Ph.D., previously CEO of Rezo Therapeutics, as its new President starting July 29, 2024. Dr. Mahmood brings a wealth of experience from within the company and the biopharmaceutical industry as a whole. His compensation includes a $530,000 annual salary, eligibility for a 50% target bonus, and a stock option for 550,000 shares. Should Dr. Mahmood leave the company under certain conditions, a severance package will be provided, with enhanced benefits if his departure coincides with a change in company control. Concurrently, the company has announced other key executive changes, demonstrating a strategic realignment of its leadership team.
For detailed information about NKTX stock, go to TipRanks’ Stock Analysis page.
